ACC 2021: PRADA Long-Term Follow-Up Suggests Cardioprotection Unnecessary for Unselected Patients Undergoing Adjuvant Breast Cancer Treatment
At 2 years, no substantial benefit with either candesartan or metoprolol were noted
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.